Oncofertility in the era of targeted therapy: Tyrosine kinase inhibitors, female reproductive toxicity, and pregnancy outcomes.

Albarakati RG, Hamza E, El-Nablaway M

Open source

DOI
10.1016/j.reprotox.2026.109237
Published
2026 Aug
Container
Reproductive toxicology (Elmsford, N.Y.)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.reprotox.2026.109237,
  title = {Oncofertility in the era of targeted therapy: Tyrosine kinase inhibitors, female reproductive toxicity, and pregnancy outcomes.},
  author = {Albarakati RG and Hamza E and El-Nablaway M},
  year = {2026},
  journal = {Reproductive toxicology (Elmsford, N.Y.)},
  doi = {10.1016/j.reprotox.2026.109237},
  url = {https://doi.org/10.1016/j.reprotox.2026.109237}
}

RIS

TY  - JOUR
TI  - Oncofertility in the era of targeted therapy: Tyrosine kinase inhibitors, female reproductive toxicity, and pregnancy outcomes.
AU  - Albarakati RG
AU  - Hamza E
AU  - El-Nablaway M
PY  - 2026
JO  - Reproductive toxicology (Elmsford, N.Y.)
DO  - 10.1016/j.reprotox.2026.109237
UR  - https://doi.org/10.1016/j.reprotox.2026.109237
ER  - 

APA

RG, A., E, H., & M, E. (2026). Oncofertility in the era of targeted therapy: Tyrosine kinase inhibitors, female reproductive toxicity, and pregnancy outcomes.. Reproductive toxicology (Elmsford, N.Y.). https://doi.org/10.1016/j.reprotox.2026.109237

Source records